Logo
x

Search

Subscribe Now

calliditas

Calliditas Reports Results from P-IIb (TRANSFORM) Study of Setanaxib for Treating Primary Biliary Cholangitis

Calliditas Reports Results from P-IIb (TRANSFORM) Study of Setanaxib for Treating Primary Biliary Cholangitis

  • July 26, 2024
Calliditas’ Nefecon Meets its Primary Endpoint in P-III Trial (NefIgArd) for the Treatment of IgA Nephropathy

Calliditas’ Nefecon Meets its Primary Endpoint in P-III Trial (NefIgArd) for the Treatment of IgA Nephropathy

  • March 13, 2023
Calliditas’ Kinpeygo Receive EC's Marketing Authorization for the Treatment of Primary Immunoglobulin A Nephropathy

Calliditas’ Kinpeygo Receive EC's Marketing Authorization for the Treatment of Primary Immunoglobulin A Nephropathy

  • July 18, 2022
Calliditas Reports First Patient Randomization in P-IIb/III (TRANSFORM) Study for Primary Biliary Cholangitis

Calliditas Reports First Patient Randomization in P-IIb/III (TRANSFORM) Study for Primary Biliary Cholangitis

  • February 15, 2022
Calliditas’s Tarpeyo (budesonide) Receives the US FDA’s Accelerated Approval for the Treatment of IgA Nephropathy

Calliditas’s Tarpeyo (budesonide) Receives the US FDA’s Accelerated Approval for the Treatment of IgA Nephropathy

  • December 15, 2021
PharmaShots Weekly Snapshots (August 09, 13, 2021)

PharmaShots Weekly Snapshots (August 09, 13, 2021)

  • August 13, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.